

Supplementary Table 1. Clinical data of CLL patients.

No	Age Yrs	Sex	IgHV Mutation	FISH Analysis	Stage (Rai)	Treatment	Treatment Agents/Course	CD160 /CD8%	CD160 /CD4%	Plasma IL-16 (pg/ml)
1	70	M	Not done, ZAP70(+)	Del13q/11q	I	T	Bendamustine + Rituximab (May-Sep.2018)	10	7.3	Not done
2	66	M	Not done, ZAP70(-)	Not done	II		N/A	9	1	Not done
3	77	M	Not done	Del17p/13q	III	T	Rituximab+ Prednisone Ibrutinib (May 2018-Apr 2020) Venetoclax (Apr 2020-Present)	Not done	Not done	Not done
4	76	M	Not done, ZAP70(-)	Del17p/13q	IV	T	FCR x 5 cycles (Mar-Jun 2010) FCR (Nov. 2015-Feb.2016) Ibrutinib (May-Sep 2016) Methylprednisolone + Rituximab (July-Sep 2018)	Not done	Not done	Not done
5	72	M	Unmutated	Trisomy 12	II		N/A	52	2.8	5000
6	51	F	Not done	Not done	I		N/A	19	0.5	1882.4
7	54	M	Unmutated	Del13q	0		N/A	17	2	472.2
8	68	M	Not done	Del13q	II		Chlorambucil + Obinutuzumab (started March 2020)	27	1.1	5500
9	75	M	Not done, ZAP70(-)	Del13q/17p (6.5%)	0	T	FCR x 2 cycles (2012)	51	0.4	444.7
10	60	F	Not done, ZAP70(-)	Not done	0		N/A	23	1.2	936.3
11	86	F	Not done	Not done	0		N/A	17	2	248.2
12	85	M	Not done	N/A	0		N/A	42	2	315.84
13	78	F	Not done	Del13q	0		N/A	52	Not done	4920.5
14	61	M	Not done	Not done	I		N/A	32	Not done	4900
15	81	M	Not done	Not done	II		N/A	38	2.2	361

Supplementary Table 1. Clinical data of CLL patients.

16	62	M	Not done	Del11q/17p	IV	T	FCR (2006), RCVP (2008), Allogenic Stem Cell transplant (2008), Ibrutinib (2015) Venetoclax+ Rituximab (2018)	25	7.5	2399.8
17	77	M	Not done	Not done	0		N/A	Not done	Not done	Not done
18	80	F	Not done	Not done	I		N/A	27	2.3	1297.8
19	63	M	Mutated ZAP70(+)	Del13q	III		Ibrutinib+Venetoclax (started Jan.2019)	29	9.8	4493.4
20	65	M	Unmutated	Del 13q	II		Ibrutinib started (Feb 2020) Switched to Acalabrutinib (Sept 2020)	Not done	Not done	1305
21	73	M	Unmutated	Normal	I		Chlorambucil (started summer 2019) Ibrutinib (started Nov. 2019)	Not done	Not done	5200
22	82	M	Not done	Not done	III	T	Bendamustine + Rituximab (Nov-Apr 2017)	23	1	265
23	74	M	Not done	Del13q	IV	T	Chlorambucil+ Obinutuzumab (Dec.2017)	22	1	Not done
24	71	F	Not done	Not done	IV	T	Bendamustine + Rituximab (Jul.2015) Ibrutinib (Aug. 2019-Nov. 2020)	41	21	Not done
25	78	F	Not done	Not done	I		N/A	13	0.5	1302.4
26	71	F	Not done	Del13q	0	T	Bendamustine + Rituximab (Jul.2015)	16	1.7	302.2
27	62	M	Not done	Del17p Del11q	I	T	Chemo+ Transplant (2008), Ibrutinib Rituximab	8	1	330.4

Supplementary Table 1. Clinical data of CLL patients.

28	63	M	Not done	Normal	I	T	Bendamustine + Rituximab (Apr. 2019)	Not done	Not done	Not done
29	74	M	Unmutated	Del11q Del17p	0		Ibrutinib (Started Mar 2021)	23	4.5	3211.5
30	70	M	Unmutated	Trisomy 12	I		Acalabrutinib + Venetoclax + Obinutuzumab (Started Aug. 2019)	52	28	Not done
31	63	F	Not done	Not done	0		N/A	34	6	384
32	68	M	Unmutated	Del11q Del13q	IV	T	FCR X 2 cycles (2017) Ibrutinib (Feb. 2019-Sept. 2020)	23		3738.3
33	53	M	Mutated	Del13q	II		Acalabrutinib+ Venetoclax + Obinutuzumab (Started Oct. 2020)	35	5	5400
34	54	M	Not done	Normal	II		N/A	Not done	Not done	147.6
35	71	M	Not done	Normal	II	T	Bendamustine + Rituximab (2014) CHOP for ALCL (2017) Ibrutinib (Jan. 2020)	15.5	9	1065
36	91	F	Not done	Not done	I	T	Chlorambucil + Obinutuzumab (Started Jun. 2017) Ibrutinib (Started May 2019)	11	12	5122
37	68	M	Not done	Not done	II		N/A	6	7.5	2599
38	72	M	Not done	Del13q Trisomy12	IV	T	Chlorambucil + Obinutuzumab (Jun. 2019)	45	4.5	4385
39	63	M	Mutated	Del13q	II	T	Ibrutinib+Venetoclax	19	15	294
40	65	F	Not done	Not done	0		N/A	14	7	2371.5
41	55	F	Not done	Not done	0		N/A (TCH chemo for Breast Ca, Jan. 2018)	13	13	971

Supplementary Table 1. Clinical data of CLL patients.

42	59	M	Indeterminate	Normal	II		Bendamustine + Rituximab (Started Sept. 2019)	Not done	Not done	4900
43	74	F	Not done	Del13q	I		N/A	18	8	577.5
44	79	F	Not done	Del13q	I	T	Chlorambucil + Obinutuzumab (Jul. 2019)	43	10	5023.6
45	70	M	Unmutated	Trisomy12	III		N/A	48	29	Not done
46	56	F	Mutated	Del13q Del11q	III		Bendamustine + Rituximab (Started Aug. 2019)	45	13	Not done
47	72	M	Not done	Normal (2019) Del11q GAIN	IV		Bendamustine + Rituximab (Aug.2019) Switch to Ibrutinib (Nov. 2019) RCHOP for Richter's (Sept. 2020)	55	18	1257.8
48	45	F	Mutated	Del13q	II		Bendamustine + Rituximab (Aug. 2019)	28	14	Not done
49	60	F	Indeterminate	Trisomy12	II		Bendamustine + Rituximab (Jun. 2019)	62	22	Not done
50	76	M	Unmutated	Trisomy12	I		Acalabrutinib + Venetoclax (Oct. 2019)	50	17	Not done
51	74	M	Unmutated	Del13q Trisomy12	I		Bendamustine + Rituximab (Oct. 2019)	49	36	Not Done
52	64	M	Mutated	Not done	0	T	Venetoclax+ Ibrutinib	30	10	Not done
53	64	M	Not done	Del13q	0		N/A	17	7	Not done
54	67	F	Not done	Not done	0		N/A	25	11	Not done
55	60	M	Not done	Not done	I		N/A	22	11.5	Not done
56	77	M	N/A	Del11q	I	T	Ibrutinib+ Obinutuzumab. (2015)	Not done	Not done	Not done

Supplementary Table 1. Clinical data of CLL patients.

							Venetoclax + Rituximab (2019)			
--	--	--	--	--	--	--	----------------------------------	--	--	--

Sex: (M: Male, F: Female),

Staging: based on Rai staging system,

T Refers to the treatment

Green (off treatment), Orange (on treatment),

N/A: Not Available